Inventiva S.A.
IVA
Hisse Senetlerindeki Sıralama
#10379
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Hisse Fiyatı
$3.36
Piyasa Değeri
$794.51M
Değişim (1 gün)
-3.85%
Değişim (1 yıl)
-8.92%
Ülke
FR
Ticaret Inventiva S.A. (IVA)
Kategori
Healthcare
Inventiva S.A. (IVA) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $3.41 - 2026-10-01
Gün sonu en düşük fiyat: $11.50 - 2021-08-01
Gün sonu en düşük fiyat: $11.50 - 2021-08-01
Inventiva S.A. için hisse fiyatı geçmişi: 2021 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 11.31% |
| 2025 | 81.18% |
| 2024 | -45.73% |
| 2023 | -3.30% |
| 2022 | -66.26% |
| 2021 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
